Topical Nasal Fluticasone Propionate in the Control of Allergic Rhinitis SymptomsPerene
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
Phase III Study to Demonstrate the non inferiority of PLURAIR® branded nasal topical
Fluticasone Propionate (FP) in relation to the FLIXONASE® brand reference drug in the control
of nasal symptoms related to perennial allergic rhinitis.